Universe Pharmaceuticals INC
UPCNasdaq
$4.45
↓ -2.2%Jul 17 close · end-of-day
Price
1Y↑ +19.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.0M
Enterprise Value
$2.1B
P/E
—
P/S
0.0
P/B
0.0
EV/EBITDA
—
PEG
—
FCF Yield
-262201.6%
Dividend Yield
—
Revenue (TTM)
$17.9B
Net Income (TTM)
-$3.7B
Free Cash Flow (TTM)
-$5.3B
Gross Margin
35.3%
Operating Margin
-16.3%
Net Margin
-20.6%
ROE
-6.5%
ROIC
-4.0%
Debt / Equity
0.0
Net Cash
-$2.1B
Return 1Y
—
Company profile
Universe Pharmaceuticals INC engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, and dietary supplements.
- CEO
- Gang Lai
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 220
- Website
- www.dzrzy.com/
Earnings
No reported earnings periods on file.
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $30.7M | $48.0M | $40.1M | $32.3B | $23.0B | $17.9B |
| Gross profit | $14.1M | $25.3M | $21.9M | $10.3B | $6.1B | $6.3B |
| Operating income | $10.3M | $13.6M | -$7.0M | -$4.0B | -$8.0B | -$2.9B |
| Net income | $7.6M | $11.3M | -$7.9M | -$6.6B | -$8.7B | -$3.7B |
| Diluted EPS | $0.47 | $3.58 | -$1,309.11 | -$1,089.21 | -$626.96 | -$8.06 |
| Operating cash flow | $6.1M | -$2.1M | -$1.3M | $1.1B | -$9.5B | -$5.1B |
| Free cash flow | $6.1M | -$2.5M | -$1.4M | $1.1B | -$9.7B | -$5.3B |
| Gross margin | 45.9% | 52.8% | 54.5% | 31.9% | 26.4% | 35.3% |
| Operating margin | 33.4% | 28.3% | -17.5% | -12.3% | -34.8% | -16.3% |
| Net margin | 24.6% | 23.6% | -19.7% | -20.4% | -37.9% | -20.6% |
No quarterly data.
Company news
Jun 26, 2026
Feb 11, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.